Top-News

F-star Therapeutics News

Aktie
WKN:  A2QJEK ISIN:  US30315R1077 US-Symbol:  FSTX
Keine aktuellen Kursdaten verfügbar
Handeln Depot/Watchlist
Dieses Wertpapier ist nicht mehr handelbar.
Aktienanzahl *
21,58 Mio.
Marktkapitalisierung *
-
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 31.12.2022

F-star Therapeutics News

07.03.23 - GlobeNewswire
F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma
Parties expect the merger to be completed promptly following the successful completion of the ongoing Tender Offer
07.03.23 - PR Newswire
Thinking about buying stock in Troika Media, Snap, F-Star Therapeutics, Ambrx Biopharma, or SoundHound AI?
Thinking about buying stock in Troika Media, Snap, F-Star Therapeutics, Ambrx Biopharma, or SoundHound AI? PR Newswire
26.01.23 - GlobeNewswire
invoX Pharma and F-star Therapeutics issue Joint Statement
LONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- invoX Pharma (“invoX”), a wholly owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK), and F-star ...
30.12.22 - PR Newswire
Thinking about buying stock in Palisade Bio, Kala Pharmaceuticals, F-Star Therapeutics, Nuwellis, or TG Therapeutics?
Thinking about buying stock in Palisade Bio, Kala Pharmaceuticals, F-Star Therapeutics, Nuwellis, or TG Therapeutics? PR Newswire
28.12.22 - PR Newswire
Thinking about buying stock in Jounce Therapeutics, Kala Pharmaceuticals, Nano-X Imaging, F-Star Therapeutics, or Pagaya Technologies?
Thinking about buying stock in Jounce Therapeutics, Kala Pharmaceuticals, Nano-X Imaging, F-Star Therapeutics, or Pagaya Technologies? PR Newswire
06.12.22 - GlobeNewswire
F-star Therapeutics Presents Clinical Data on FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, at ESMO-IO 2022 Congress
FS222 demonstrated early antitumor activity with one complete response and six disease stabilizations in patients with advanced solid tumors
07.11.22 - GlobeNewswire
F-star Therapeutics Announces Publication of Phase 1 Dose-Escalation Trial of FS118 in Patients with Advanced Cancer and PD-L1 Resistance in Clinical Cancer Research
- FS118 is Well-​Tolerated Across all Dose Levels with No Serious Adverse Events Related to FS118 Therapy - Novel mechanism showing Increased Peripheral Immune Cells and ...
05.10.22 - PR Newswire
F-STAR THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of F-star Therapeutics, Inc. - FSTX
F-STAR THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in ...
11.08.22 - GlobeNewswire
F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
Previously announced agreement for F-star Therapeutics to be acquired by invoX Pharma; transaction expected to close in the second half of 2022 License Agreement with Takeda ...
21.07.22 - PR Newswire
SHAREHOLDER ALERT: Weiss Law Reminds FSTX, STCN, GRRB, and ZEN Shareholders About Its Ongoing Investigations
SHAREHOLDER ALERT: Weiss Law Reminds FSTX, STCN, GRRB, and ZEN Shareholders About Its Ongoing Investigations PR Newswire
20.07.22 - GlobeNewswire
F-star Therapeutics Announces a License Agreement with Takeda for a Novel Next-Generation Immuno-oncology Bispecific Antibody
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) --
12.07.22 - PR Newswire
SHAREHOLDER ALERT: Weiss Law Reminds FSTX, STCN, GRRB, and OBCI Shareholders About Its Ongoing Investigations
SHAREHOLDER ALERT: Weiss Law Reminds FSTX, STCN, GRRB, and OBCI Shareholders About Its Ongoing Investigations PR Newswire
11.07.22 - PR Newswire
INVESTIGATION NOTICE: Halper Sadeh LLP Investigates DRE, RDUS, FSTX, RADA, USAK
INVESTIGATION NOTICE: Halper Sadeh LLP Investigates DRE, RDUS, FSTX, RADA, USAK PR Newswire
06.07.22 - PR Newswire
SHAREHOLDER ALERT: Weiss Law Reminds FSTX, ZEN, RDUS, and EPZM Shareholders About Its Ongoing Investigations
SHAREHOLDER ALERT: Weiss Law Reminds FSTX, ZEN, RDUS, and EPZM Shareholders About Its Ongoing Investigations PR Newswire
30.06.22 - PR Newswire
SHAREHOLDER ALERT: Weiss Law Reminds FSTX, ZEN, MANT, and RTLR Shareholders About Its Ongoing Investigations
SHAREHOLDER ALERT: Weiss Law Reminds FSTX, ZEN, MANT, and RTLR Shareholders About Its Ongoing Investigations PR Newswire
27.06.22 - PR Newswire
Investor Alert - The M&A Class Action Firm Announces an Investigation of F-star Therapeutics, Inc. - FSTX
Investor Alert - The M&A Class Action Firm Announces an Investigation of F-star Therapeutics, Inc. - FSTX PR Newswire
24.06.22 - PR Newswire
SHAREHOLDER ALERT: Weiss Law Investigates F-star Therapeutics, Inc.
SHAREHOLDER ALERT: Weiss Law Investigates F-star Therapeutics, Inc. PR Newswire
24.06.22 - Der Aktionär
Übernahmewelle voraus? Nächster Deal im Biotech‑Sektor – 79 Prozent Aufschlag
23.06.22 - GlobeNewswire
invoX Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical Programs
Proposed ~US$161 million all-cash acquisition to accelerate invoX’s strategy to build Sino Biopharm’s International Biopharmaceutical R&D Platform outside of China, transforming ...
23.06.22 - PR Newswire
Shareholder Alert: Ademi LLP investigates whether F-star Therapeutics, Inc. has obtained a Fair Price in its transaction with invoX
Shareholder Alert: Ademi LLP investigates whether F-star Therapeutics, Inc. has obtained a Fair Price in its transaction with invoX PR Newswire

Newssuche

Videos

newspaper
23.05.24 +3,63%
Technical Trading: Sojabohnen im saisonalen Trend
Sojabohnen Long Typ: Turbo Open End WKN: VX41AH Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »